Lub-de Hooge M N, de Vries E G E, de Jong S, Bijl M
Department of Clinical Immunology University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, Netherlands.
Ann Rheum Dis. 2005 Jun;64(6):854-8. doi: 10.1136/ard.2004.029058. Epub 2004 Nov 25.
Increased apoptosis may induce autoimmune conditions. Apoptosis is induced by binding of death receptor ligands, members of the tumour necrosis factor (TNF) superfamily, to their cognate receptors. The Fas-Fas ligand pathway has been studied extensively in relation to systemic lupus erythematosus (SLE). However, other death pathways are also considered important. TNF related apoptosis inducing ligand (TRAIL), another ligand of the TNF superfamily, induces apoptosis in sensitive cells.
To assess soluble (s) TRAIL concentrations in sera of SLE patients.
40 SLE patients were studied (20 with active and 20 with inactive disease). Serum sTRAIL concentrations were measured by a solid phase sandwich enzyme linked immunosorbent assay. Levels in SLE patients were compared with those in patients with rheumatoid arthritis (n = 20), Wegener's granulomatosis (n = 20), and healthy controls (n = 20).
Mean (SEM) serum sTRAIL concentration in SLE patients (936.0 (108.2) pg/ml) was higher than in healthy controls (509.4 (33.8) pg/ml; p<0.01) or in disease control patients with rheumatoid arthritis (443.8 (36.1) pg/ml, p<0.001) or Wegener's granulomatosis (357.1 (32.2) pg/ml; p<0.001). The mean serum sTRAIL concentration was 1010.2 (168.0) pg/ml for patients with inactive disease and 861.8 (138.7) pg/ml for those with active disease. sTRAIL values were not correlated with specific manifestations of the disease, such as leucopenia or lymphopenia, or with SLE disease activity index.
Serum sTRAIL concentrations are increased SLE patients. This seems to be disease specific and could indicate a role for TRAIL in SLE pathophysiology.
凋亡增加可能诱发自身免疫性疾病。凋亡是由肿瘤坏死因子（TNF）超家族成员死亡受体配体与其同源受体结合所诱导的。Fas - Fas配体途径已针对系统性红斑狼疮（SLE）进行了广泛研究。然而，其他死亡途径也被认为很重要。TNF相关凋亡诱导配体（TRAIL）是TNF超家族的另一种配体，可诱导敏感细胞凋亡。
评估SLE患者血清中可溶性（s）TRAIL的浓度。
对40例SLE患者进行研究（20例为活动期患者，20例为非活动期患者）。采用固相夹心酶联免疫吸附测定法检测血清sTRAIL浓度。将SLE患者的水平与类风湿关节炎患者（n = 20）、韦格纳肉芽肿患者（n = 20）和健康对照者（n = 20）的水平进行比较。
SLE患者血清sTRAIL平均（SEM）浓度（936.0（108.2）pg/ml）高于健康对照者（509.4（33.8）pg/ml；p<0.01），或类风湿关节炎疾病对照患者（443.8（36.1）pg/ml，p<0.001）以及韦格纳肉芽肿患者（357.1（32.2）pg/ml；p<0.001）。非活动期疾病患者的血清sTRAIL平均浓度为1010.2（168.0）pg/ml，活动期疾病患者为861.8（138.7）pg/ml。sTRAIL值与疾病的特定表现如白细胞减少或淋巴细胞减少无关，也与SLE疾病活动指数无关。
SLE患者血清sTRAIL浓度升高。这似乎具有疾病特异性，可能表明TRAIL在SLE病理生理学中起作用。
